Literature DB >> 27294006

ATPase inhibitory factor 1 expression is an independent prognostic factor in non-small cell lung cancer.

Yi-Xing Gao1, Lu Chen1, Xu-Gang Hu1, Hai-Bo Wu1, You-Hong Cui1, Xia Zhang1, Yan Wang1, Xin-Dong Liu1, Xiu-Wu Bian2.   

Abstract

ATPase inhibitory factor 1 (IF1), an inhibitor of the mitochondrial H(+)-adenosine triphosphate (ATP) synthase, is putatively involved in tumor progression. This study aimed to evaluate the expression levels of IF1 in non-small cell lung cancer (NSCLC) and the prognostic value for the patients. IF1 protein expression levels were detected in 149 cases of NSCLC by using immunohistochemistry. Kaplan-Meier analysis showed that NSCLC patients with high expression of IF1 possessed poorer outcome than those with low expression of IF1 (P=0.007). Moreover, IF1 was also prognostic in the patients with early stages (stage I/II) (P=0.042) and low grade (grade I/II) (P=0.002). Multivariable Cox-regression analysis showed that high expression of IF1 (HR=1.67, P=0.034), tumor size (HR=1.79, P=0.001), and lymph node metastasis (HR=2.66, P=0.000) were independent indicators for NSCLC patients. In conclusion, our study demonstrated that elevated expression of IF1 may associated with lymph node metastasis of NSCLC and served as an independent prognostic and recurrent indicator for the patients.

Entities:  

Keywords:  IF1; lymph node metastasis; non-small cell lung cancer; prognosis

Year:  2016        PMID: 27294006      PMCID: PMC4889727     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  32 in total

1.  The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics.

Authors:  Simona Barbato; Gianluca Sgarbi; Giulia Gorini; Alessandra Baracca; Giancarlo Solaini
Journal:  J Biol Chem       Date:  2015-01-20       Impact factor: 5.157

2.  Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma.

Authors:  Feng Wu; Qi Zhou; Jing Yang; Guang-jie Duan; Juan-juan Ou; Rong Zhang; Feng Pan; Qiu-ping Peng; Hong Tan; Yi-fang Ping; You-hong Cui; Cheng Qian; Xiao-chu Yan; Xiu-wu Bian
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients.

Authors:  Shuta Tomida; Katsumi Koshikawa; Yasushi Yatabe; Tomoko Harano; Nobuhiko Ogura; Tetsuya Mitsudomi; Masato Some; Kiyoshi Yanagisawa; Toshitada Takahashi; Hirotaka Osada; Takashi Takahashi
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

Review 6.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

7.  A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays.

Authors:  Wei Huang; Kenneth Hennrick; Sally Drew
Journal:  Hum Pathol       Date:  2012-08-31       Impact factor: 3.466

8.  Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance.

Authors:  Daniel J O'Shannessy; Gordon Yu; Robert Smale; Yao-Shi Fu; Sunil Singhal; Robert P Thiel; Elizabeth B Somers; Anil Vachani
Journal:  Oncotarget       Date:  2012-04

9.  Clinical investigation into the initial diagnosis and treatment of 1,168 lung cancer patients.

Authors:  Qian Shao; Jianbin Li; Fengxiang Li; Suzhen Wang; Wei Wang; Shanshan Liu; Yingjie Zhang
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

10.  Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state.

Authors:  Fulvio Santacatterina; Laura Sánchez-Cenizo; Laura Formentini; Maysa A Mobasher; Estela Casas; Carlos B Rueda; Inmaculada Martínez-Reyes; Cristina Núñez de Arenas; Javier García-Bermúdez; Juan M Zapata; María Sánchez-Aragó; Jorgina Satrústegui; Ángela M Valverde; José M Cuezva
Journal:  Oncotarget       Date:  2016-01-05
View more
  10 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

2.  ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma.

Authors:  Xuemei Ding; Jian Kong; Wenlei Xu; Shuying Dong; Yingrui Du; Changyu Yao; Jun Gao; Shan Ke; Shaohong Wang; Wenbing Sun
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

Review 3.  Regulation of the H+-ATP synthase by IF1: a role in mitohormesis.

Authors:  Pau B Esparza-Moltó; Cristina Nuevo-Tapioles; José M Cuezva
Journal:  Cell Mol Life Sci       Date:  2017-02-06       Impact factor: 9.261

4.  Overexpression of the ATPase Inhibitory Factor 1 Favors a Non-metastatic Phenotype in Breast Cancer.

Authors:  Lucía García-Ledo; Cristina Nuevo-Tapioles; Carmen Cuevas-Martín; Inmaculada Martínez-Reyes; Beatriz Soldevilla; Lucía González-Llorente; José M Cuezva
Journal:  Front Oncol       Date:  2017-04-10       Impact factor: 6.244

Review 5.  The Role of Mitochondrial H+-ATP Synthase in Cancer.

Authors:  Pau B Esparza-Moltó; José M Cuezva
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

6.  Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth.

Authors:  Cristina Nuevo-Tapioles; Fulvio Santacatterina; Konstantinos Stamatakis; Cristina Núñez de Arenas; Marta Gómez de Cedrón; Laura Formentini; José M Cuezva
Journal:  Nat Commun       Date:  2020-07-17       Impact factor: 14.919

7.  Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy.

Authors:  Laura Torresano; Fulvio Santacatterina; Sonia Domínguez-Zorita; Cristina Nuevo-Tapioles; Alfonso Núñez-Salgado; Pau B Esparza-Moltó; Lucía González-Llorente; Inés Romero-Carramiñana; Cristina Núñez de Arenas; Brenda Sánchez-Garrido; Laura Nájera; Clara Salas; Mariano Provencio; José M Cuezva
Journal:  Oncogenesis       Date:  2022-05-09       Impact factor: 6.524

Review 8.  The F1Fo-ATPase inhibitor protein IF1 in pathophysiology.

Authors:  Cristina Gatto; Martina Grandi; Giancarlo Solaini; Alessandra Baracca; Valentina Giorgio
Journal:  Front Physiol       Date:  2022-08-04       Impact factor: 4.755

9.  F1F0-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation.

Authors:  Helen Tanton; Svetlana Voronina; Anthony Evans; Jane Armstrong; Robert Sutton; David N Criddle; Lee Haynes; Michael C Schmid; Fiona Campbell; Eithne Costello; Alexei V Tepikin
Journal:  Front Physiol       Date:  2018-07-11       Impact factor: 4.566

Review 10.  The Multifaceted ATPase Inhibitory Factor 1 (IF1) in Energy Metabolism Reprogramming and Mitochondrial Dysfunction: A New Player in Age-Associated Disorders?

Authors:  Emilia Gore; Thibaut Duparc; Annelise Genoux; Bertrand Perret; Souad Najib; Laurent O Martinez
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 7.468

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.